Home Medizin UMSOM erhält BARDA-Auftrag über 3,5 Millionen US-Dollar zur Entwicklung von Tiermodellen für die Strahlenforschung

UMSOM erhält BARDA-Auftrag über 3,5 Millionen US-Dollar zur Entwicklung von Tiermodellen für die Strahlenforschung

von NFI Redaktion

Mark T. Gladwin, MD, the Dean of the University of Maryland School of Medicine (UMSOM), announced today that scientists from the UMSOM faculty have been selected by the Biomedical Advanced Research and Development Authority (BARDA) as the prime contractor for the development of radioactive animal models under the federal agency’s program. The $3.5 million award received by Erika Davies, PhD, Assistant Professor of Radiation Oncology, for the development of animal models for acute radiation syndrome has a potential total value of $16 million. The Department of Translational Radiation Sciences (DTRS) within the Department of Radiation Oncology will support this project.

Dr. Davies and her colleagues are collaborating with BARDA to advance the development of radiological and nuclear countermeasures. This is part of a broader effort to enhance national preparedness for radiation incidents and emergencies. „We are working on developing and testing new treatments that could be used in a high radiation exposure terrorist attack scenario,“ said Dr. Davies. „We are developing robust animal models that can be effectively translated to humans.“

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services (DHHS).

Currently, there are relatively few medical treatments available to combat radiological and nuclear threats, as extensive preclinical efficacy and safety data are required to support drug approval by the FDA. Due to the variety of ways terrorists could use and the need for urgent interventions following radiation exposure, much more of such drugs are needed.

„DTRS is uniquely positioned to provide leading expertise in research on medical countermeasures. We combine top-notch radiation science with contract research to increase survival likelihood in a radiation or nuclear accident while identifying a potential new class of therapeutics for cancer patients undergoing radiotherapy.“

William Regine, MD, Isadore & Fannie Schneider Foxman Chair in Radiation Oncology at UMSOM

Nearly a decade ago, research conducted by DTRS faculty and staff led to the approval of the first drug to treat the harmful effects of radiation exposure following a nuclear incident, based on efficacy data gathered in animal models. Animal models are particularly important in preparing for radiation emergencies, as the efficacy of most experimental treatments cannot be tested on humans.

„DTRS is able to develop various experimental models using its state-of-the-art ‚Good Laboratory Practice‘ compliant testing facility, which houses one of the best-equipped technologies to support the nation’s radiation research,“ said Dr. Gladwin, the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM and Vice President for Medical Affairs at the University of Maryland, Baltimore. „The collaborative expertise of our faculty from the broadest spectrum of countermeasure investigations enables rapid configuration and implementation of solution-oriented approaches even for the most challenging issues.“

Working with BARDA will involve several individual projects, relying on changing configurations of DTRS experts, instruments, and specialized resources, as well as collaborations with other researchers from UMSOM and the University of Maryland, Baltimore.


University of Maryland School of Medicine

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.